Zhimei Du

Dr. Zhimei Du is a leader in the fields of Cell/Gene Therapy and Biologics with significant experience in both early and late-stage development. Currently serving as Vice President at Landmark Bio, she leads the Translational Research and Early Development of next-generation cell/gene therapies for various diseases. Prior to joining Landmark Bio, Dr. Du served as Vice President at Atara Biotherapeutics, where she focused on accelerating both early and late-stage cell therapy pipelines. She also worked at Merck & Co. as Executive Director and Global Head of Process Cell Sciences, where she established various new core functions in cell therapy and biologics during early development. Dr. Du has also been actively involved in successful business development activities, including evaluating and building partnerships for CAR-T and CAR-NK programs. Her research contributions include numerous patents and publications in cell and gene therapy, process development, protein engineering, cell engineering, vector engineering, and genetic/epigenetic biomarker development. Dr. Du received her Ph.D. in Immunology from Cornell University Medical College. She then worked as a Postdoctoral Fellow in Robert G. Roeder's laboratory at Rockefeller University, a world-renowned lab known for its groundbreaking work in transcription, in vitro transcription, and epigenetics.